Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters

Hypertension Research

Volumn 27, Issue 3, 2004, Pages 141-145

  Inaba, Munemichi ^a   Noguchi, Yuichi ^a   Yamamoto, Taro ^a   Imai, Tomihiko ^a   Hatano, Masako ^a   Yagi, Shinji ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Ambulatory blood pressure monitoring; Hypertension; Indapamide; Low dose diuretic treatment; Metabolic parameters

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; SODIUM; TRIACYLGLYCEROL; URIC ACID;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMATOCRIT; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; METABOLIC PARAMETERS; POTASSIUM BLOOD LEVEL; SODIUM BLOOD LEVEL; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; URIC ACID;

EID: 1842856032     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.141     Document Type: Article

References (21)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2449.
2. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
3. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
4. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412.
5. Psaty BM, Smith NL, Siscovick DS, et al: Health outcomes associated with antihypertensive therapies used as first-line agents: a systemic review and meta-analysis. JAMA 1997; 277: 739-745.
6. PROGRESS Collaborative Research Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antiltypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
8. Chobanian AV, Bakris GL, Black H, et al: The seventh report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
9. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
10. Siscovick DS, Raghunathan TE, Psaty B, et al: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-1857.
11. Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS: Excess mortality associated with diuretic therapy in diabetic mellitus. Arch Intern Med 1991; 151: 1350-1356.
12. Carlsen JE, Kober L, Trop-Pedersen C, Johansen P: Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975-978.
13. Kuwajima I, Kuramoto K, Ogihara T, et al, on behalf of National Intervention Cooperative Study in Elderly Hypertensive (NICS-EH) Study Group: Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH. Hypertens Res 2001; 24: 475-480.
14. Iseki K, Iseki C, Itoh K, et al: Urinary excretion of sodium and potassium in a screened cohort in Okinawa, Japan. Hypertens Res 2002; 25: 731-736, 2002.
15. Baba S, Amano M, Iimura M, et al: Safety of indapamide on essential hypertensive patients in long-term administration. Geriatr Med 1982; 20: 1207-1216 (in Japanese).
16. Kitao K, Sakata T, Ueshima Y, Muro H, Fujitani M, Murauchi H: Phase 1 clinical study of a new non-thiazide antihypertensive drug, indapamide. Pharmacol Ther 1982; 10: 2619-2631 (in Japanese).
17. Campbell DB, Taylor A, Moore RA: Observations on the pharmacokinetics of indapamide. Br J Clin Pharmacol 1976 ; 3: 971.
18. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025-1030.
19. Pollare T, Lithel H, Berne C: A comparison of hydrochrolothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873.
20. Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-616.
21. Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.